Cerebrovascular disease is the general term for cerebrovascular diseases caused by various causes. Stroke is the main clinical type of cerebrovascular disease, including ischemic stroke and hemorrhagic stroke. Stroke is one of the major diseases that endanger the health and life of middle-aged and elderly people. In the third national survey on causes of death published by the Ministry of Health in 2008, stroke has overtaken malignant tumors as the number one cause of death in China, and the high morbidity, mortality and disability rates of this disease bring heavy burden and pain to the society and families. Ischemic stroke is cerebral infarction, also known as cerebral thrombosis and cerebral infarction. It is a clinical syndrome in which the blood supply to the brain is impaired due to various causes, resulting in ischemic and hypoxic necrosis of local brain tissue and corresponding neurological deficits, and cerebral infarction is the most common type of stroke, accounting for about 70%-80%. According to TOAST typing, it can be divided into ①: large artery atherosclerosis type. ②: Cardiogenic embolism. ③: Small artery occlusion type. ④: Other etiology type. ⑤: unexplained type. The main risk factors for ischemic stroke include: hypertension, smoking, diabetes, dyslipidemia, atrial fibrillation, heart valve disease, endocardial disease, cardiomyopathy, asymptomatic carotid stenosis, and obesity; there are also non-interventional risk factors: age, gender, genetics, race, and low birth weight. The common clinical manifestations of ischemic stroke include sudden onset of unfavorable speech, weakness or numbness of the lateral limbs, slanting of the mouth, double vision, choking on water, and dizziness. The key to early treatment of ischemic stroke is revascularization, which is fundamental to treatment. since 1995, several relevant clinical trials have laid the foundation for the era of standard intravenous thrombolysis represented by recombinant fibrinogen activator (rt-PA), which has entered a mature stage of intravenous thrombolysis with the advancement of practice and knowledge. Guidelines from various countries have taken thrombolysis as the highest level of recommendation for acute ischemic stroke, including the Chinese Medical Association guidelines: for patients within 3h of ischemic stroke onset, rt-PA thrombolysis should be given intravenously as soon as possible according to strict screening of indications (Class I recommendation, Level A evidence) However, in China, for various reasons, the thrombolysis rate is extremely low, far from the average international thrombolysis rate. This is especially true in Shenzhen.